These findings support the hypothesis that the orexin A could be considered as an emerging biomarker for various endocrine disorders including diabetes mellitus and obesity which ultimately leads to various cardiovascular risk factors (Monda et al., 2006; Di Rosa et al., 2013; Bramanti et al., 2016; Mondola et al., 2016; Rani et al., 2017). This evidence concerns the gene HCRT and obesity disorder.